Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

BACKGROUND: We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. METHODS: SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Neurol
Päätekijät: Loo, Li Shen, Plato, Brian M., Turner, Ira M., Case, Michael G., Raskin, Joel, Dowsett, Sherie A., Krege, John H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691529/
https://ncbi.nlm.nih.gov/pubmed/31409292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-019-1420-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia